PA
AVBP icon

Profund Advisors’s ArriVent BioPharma AVBP Stock Holding History

Profund Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$388K Buy
16,813
+5,829
+53% +$132K 0.01% 638
2025
Q4 		$221K Buy
+10,984
New +$229K 0.01% 1101

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Profund Advisors's AVBP Position: Q1 2026 in Review

Profund Advisors increased its ArriVent BioPharma (AVBP) stake by 53% in Q1 2026, buying an estimated $132K and bringing the position to 16,813 shares worth $388K. The position accounts for 0.01% of the portfolio, ranked #638.

Profund Advisors first reported a position in AVBP in Q4 2025 and has held it in 2 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Profund Advisors held 16,813 shares of ArriVent BioPharma worth $388K as of Q1 2026.
  • Profund Advisors bought 5,829 ArriVent BioPharma shares in Q1 2026, an estimated $132K.
  • ArriVent BioPharma made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #638 holding.
  • Profund Advisors first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.